Skip to main content
. Author manuscript; available in PMC: 2017 Nov 20.
Published in final edited form as: Leukemia. 2016 Dec 9;31(3):751–754. doi: 10.1038/leu.2016.340

Figure 1.

Figure 1

PRL2 is important for the proliferation and survival of human T-ALL cells. (a) PRL2 is highly expressed in both primary human B-ALL and T-ALL cells (Normal control cells were set to 1).8 (b) Tail-7 cells were transduced with lentiviruses expressing control or PRL2 shRNA. The proliferation of transduced cells (GFP+) was measured over time (*p<0.05, n=3). (c) Tail-7 cells were transduced with lentiviruses expressing control or PRL2 shRNA were cultured with or without IL-7 for 2 days. The percentage of apoptotic cells was measured by Annexin V and PI staining (*p<0.05, n=3). (d) Inhibiting of PRL2 activity with a small molecule inhibitor (PRLi) decreases the viability of human T-ALL cell lines in a dosage-dependent manner. (e) Treatment of human T-ALL cell lines with PRL2 inhibitor (PRLi) induces apoptosis (***p<0.001, n = 3). (f) Immunoblot analysis of ERK phosphorylation in human T-ALL cells following DMSO or a small molecule inhibitor (PRLi) treatment. Representative Western blot analysis of indicated proteins is shown.